Results 231 to 240 of about 88,749 (308)

Cyclam-Modified Polyethyleneimine for Simultaneous TGFβ siRNA Delivery and CXCR4 Inhibition for the Treatment of CCl₄-Induced Liver Fibrosis [Retraction]. [PDF]

Int J Nanomedicine
europepmc   +1 more source

CXCR4 antagonistic lipid nanoparticles loading siRNA combat refractory AML through AML1-ETO depletion and homoharringtonine sensitization. [PDF]

Mater Today Bio
Peng X, Gu R, Wang T, Jiang C, Xing H, Meng J, Wen T, Wang J, Liu J, Xu H.   +9 more
europepmc   +1 more source

Lung Pericytes: Molecular Mechanisms, Signaling Pathways, and Roles in Pulmonary Diseases

Comprehensive Physiology, Volume 16, Issue 4, August 2026.
Central role of pericytes across major pulmonary diseases. Conceptual wheel diagram illustrating the central role of lung pericytes across diverse pulmonary disease states. A pericyte positioned at the center expresses canonical markers, including PDGFRβ, CD146, and NG2, and connects radially to five major disease contexts.
Stuti Agarwal, Anuradha Bankar, Vinicio A. de Jesus Perez   +2 more
wiley   +1 more source

Insights into the context-dependent immunological roles of the CXCL12-CXCR4 axis in alopecia. [PDF]

Front Immunol
Sung JH, Zheng M, Park IG, An S, Cho J, Noh M.   +5 more
europepmc   +1 more source

From scarring to healing: Emerging regenerative therapies for pulmonary fibrosis using MSCs and exosomes

Clinical and Translational Discovery, Volume 6, Issue 4, August 2026.
MSCs exert anti‐inflammatory, anti‐fibrotic and regenerative effects in pulmonary fibrosis. MSC‐derived exosomes reproduce many therapeutic benefits of parental MSCs. Preconditioning and genetic modification improve MSC therapeutic performance. Current preclinical and clinical evidence supports the translational potential of MSC‐based therapies ...
Hajar Nasiri, Farbod Khosravi, Fatemeh Eskandari, Tahereh Manoochehrabadi, Ali Samadikuchaksaraei, Ehsan Lotfi, Jila Majidi, Fatemeh Rafati, Zeynab Ghorbani   +8 more
wiley   +1 more source

Single-cell and spatial transcriptomics reveal that the CXCL12-CXCR4 axis drives the immune-desert phenotype in small cell lung cancer by recruiting immunosuppressive CXCR4⁺ neutrophils and S100A8⁺ monocytes. [PDF]

J Immunother Cancer
Zeng P, Li HF, Shu WB, Zhang J, Zhao TC, Hu JW, Wang JF, Wang C, Lu QY, Yang JH, An YL, Chen R.   +11 more
europepmc   +1 more source

Sphingosine‐1‐Phosphate Receptor 1 Promotes Ovarian Cancer Tumorsphere Proliferation and Metastasis

International Journal of Cancer, Volume 159, Issue 3, Page 768-781, 1 August 2026.
In high‐grade serous ovarian cancer, malignant ascites frequently arise as ovarian cancer cells shed from the primary tumor and aggregate into tumorspheres, severely limiting treatment success. To date, little is known about the mechanisms governing tumorsphere endurance and metastasis within the ascites once formed.
Núria Gendrau‐Sanclemente, Agnès Figueras, Ferran Medina‐Jover, Juan A. Marín‐Jiménez, Michelle De Leeuw, Tianyu Dai, Marina Moreno‐Mosquera, Andrea Morales, Marc Guiu, Josefina Casas, José Carlos Perales, Roger R. Gomis, Francesc Viñals   +12 more
wiley   +1 more source

Bone Marrow Pathology in Cold Agglutinin‐Mediated Autoimmune Hemolytic Anemia: A Study of 56 Cases

European Journal of Haematology, Volume 117, Issue 2, Page 384-395, August 2026.
ABSTRACT Cold agglutinin disease (CAD) is a rare form of autoimmune hemolytic anemia (AIHA). CAD occurs in the context of a small clonal B‐cell lymphoproliferation restricted to blood and/or bone marrow (BM), without overt or extramedullary lymphoma. The WHO‐HAEM5 introduced a description of the CAD‐associated lymphoproliferative disorder (CAD‐LPD) in ...
Anne‐Marie L. Becking, Sophie J. Bernelot Moens, Marie José Kersten, Femke V. M. Mulder, Steven T. Pals, Lianne Koens, Josephine M. I. Vos   +6 more
wiley   +1 more source

From Time‐Limited Therapy to Treatment‐Free Observation: The Evolving Role of MRD in CLL Management

European Journal of Haematology, Volume 117, Issue 2, Page 305-319, August 2026.
ABSTRACT The integration of measurable residual disease (MRD) into the management of chronic lymphocytic leukemia (CLL) has emerged as a major advance in risk stratification and trial design, particularly in the context of time‐limited, targeted regimens.
Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, Antonella Bruzzese, Maria Eugenia Alvaro, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Mamdouh Skafi, Valter Gattei, Fortunato Morabito, Massimo Gentile   +13 more
wiley   +1 more source

CXCR4 in colorectal cancer: from prognostic marker to immunotherapy guide? [PDF]

BMJ Oncol
Chen CY, Lee O.
europepmc   +1 more source